Combined Angioplasty and Pharmacological Intervention Versus Thrombolysis Alone in Acute Myocardial Infarction (CAPITAL AMI Study)
Michel R. Le May, MD, FACC*,
George A. Wells, PhD,
Marino Labinaz, MD, FACC,
Richard F. Davies, MD, FACC,
Michele Turek, MD,
Danielle Leddy, MD,
Justin Maloney, MD,
Tim McKibbin, MD,
Brendan Quinn, MD,
Rob S. Beanlands, MD,
Chris Glover, MD,
Jean-François Marquis, MD,
Edward R. O’Brien, MD, FACC,
William L. Williams, MD, FACC and
Lyall A. Higginson, MD, FACC
Division of Cardiology, University of Ottawa, Ottawa, Ontario, Canada.
View larger version (30K):
[in a new window]
|
Figure 1 Randomization and disposition of patients.
|
|
View larger version (13K):
[in a new window]
|
Figure 2 Kaplan-Meier curves showing the cumulative incidence of the primary end point at 30 days and at six months. The primary end point was a composite of death, reinfarction, recurrent unstable ischemia, or stroke after random assignment to treatment with tenecteplase (TNK) alone or TNK-facilitated angioplasty. In the TNK-facilitated angioplasty group, there was a 58% relative reduction in the risk of the primary end point at 30 days (log-rank p = 0.03) (top). At six months, there was a 53% reduction in the risk of the primary end point in the TNK-facilitated angioplasty group (log-rank p = 0.03) (bottom).
|
|
|
